AbbVie: 5 Reasons That Make A Buy Case


  • AbbVie’s weak stock price performance in the past quarter is in no way an indication of the progress it has made in recent months.
  • Turnaround in revenue growth following Humira’s patent expiration is now evident and recent acquisitions could bolster growth further.
  • EPS trends have improved too, while a stable operating income is also encouraging.
  • The market multiples assessed in three ways are also more attractive than not, and the dividend yield isn’t bad either.



Since I last wrote about the pharmaceuticals company AbbVie Inc. (NYSE:ABBV) in March, its stock market performance has been underwhelming, with a 3% price decline. This isn’t an entirely surprising short-term movement.

The stock was trading at higher multiples

Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, but may initiate a beneficial Long position through a purchase of the stock, or the purchase of call options or similar derivatives in ABBV over the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha’s Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Leave a Reply

Your email address will not be published. Required fields are marked *